| P50 | author | Thomas S Griffith | Q56958439 |
| | Katherine A Murphy | Q61086767 |
| P2093 | author name string | Thomas S Griffith | |
| | Katherine A Murphy | |
| P2860 | cites work | Neutrophil infiltration into human gliomas | Q48102911 |
| | Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity | Q48632166 |
| | A vaccine targeting mutant IDH1 induces antitumour immunity | Q48649314 |
| | Effects of treatment on long-term survivors with malignant astrocytomas | Q48847104 |
| | Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells | Q24601213 |
| | Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 |
| | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 |
| | Current vaccine trials in glioblastoma: a review | Q26828965 |
| | The interaction of anticancer therapies with tumor-associated macrophages | Q27016634 |
| | Is the brain "an immunologically privileged site"? 3. Studies based on homologous skin grafts to the brain and subcutaneous tissues. | Q51233176 |
| | Residual function following hemispherectomy for tumour and for infantile hemiplegia. | Q51339551 |
| | CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice | Q83201956 |
| | Structural and functional features of central nervous system lymphatic vessels | Q27316769 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | The blockade of immune checkpoints in cancer immunotherapy | Q27860852 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations | Q28075712 |
| | Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 |
| | Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival | Q28251910 |
| | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 |
| | CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Q29614348 |
| | Nitric oxide and macrophage function | Q29615327 |
| | Malignant gliomas in adults | Q29615708 |
| | Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 |
| | Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN | Q29619346 |
| | CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. | Q30402063 |
| | Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain | Q31148056 |
| | Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation | Q33784134 |
| | NK cell-based immunotherapy for malignant diseases | Q33827433 |
| | Temozolomide and treatment of malignant glioma. | Q33983627 |
| | Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. | Q34032023 |
| | Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells | Q34072679 |
| | Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance | Q34111451 |
| | Overview of cellular immunotherapy for patients with glioblastoma. | Q34189694 |
| | The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity | Q34232543 |
| | Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Q34276759 |
| | OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity | Q34477650 |
| | Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 |
| | The B7-CD28 superfamily | Q34575331 |
| | The blood-brain barrier and cancer: transporters, treatment, and Trojan horses | Q34577796 |
| | Macrophage regulation of tumor responses to anticancer therapies | Q34649588 |
| | Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo | Q34666875 |
| | Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis | Q34713380 |
| | Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy | Q34764143 |
| | Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. | Q34853757 |
| | Mast cells as targets for immunotherapy of solid tumors. | Q38201926 |
| | Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential | Q38414485 |
| | Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model | Q38821358 |
| | T cells redirected to EphA2 for the immunotherapy of glioblastoma | Q39258646 |
| | CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. | Q39303777 |
| | An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas | Q39316966 |
| | A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. | Q39637223 |
| | Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. | Q39972447 |
| | In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma | Q40042353 |
| | Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment | Q40400501 |
| | Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 |
| | Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation | Q41019909 |
| | The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses | Q41779891 |
| | HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors | Q41783221 |
| | Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites | Q42089231 |
| | CONDITIONS DETERMINING THE TRANSPLANTABILITY OF TISSUES IN THE BRAIN. | Q42787795 |
| | Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. | Q43508744 |
| | Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. | Q44783246 |
| | Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma | Q45712444 |
| | Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. | Q45879987 |
| | NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain | Q46126574 |
| | Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology | Q46175398 |
| | Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration | Q46720423 |
| | Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. | Q34982039 |
| | CSF-1R inhibition alters macrophage polarization and blocks glioma progression | Q34993852 |
| | Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells | Q35111932 |
| | EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma | Q35145144 |
| | Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors | Q35162055 |
| | B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. | Q35444346 |
| | CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. | Q35546240 |
| | Neutrophils promote the malignant glioma phenotype through S100A4. | Q35577475 |
| | Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells | Q35740077 |
| | Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma | Q35741739 |
| | Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. | Q35790354 |
| | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma | Q35815273 |
| | CD4 cells can be more efficient at tumor rejection than CD8 cells | Q35839925 |
| | Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer | Q36057441 |
| | Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. | Q36248008 |
| | Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma | Q36321176 |
| | Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. | Q36368090 |
| | The central role of CD4(+) T cells in the antitumor immune response | Q36401381 |
| | Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas | Q36478070 |
| | Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma | Q36523499 |
| | Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. | Q36639475 |
| | Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma | Q36696205 |
| | Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment | Q36746004 |
| | Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond | Q36845643 |
| | Diffuse glioma growth: a guerilla war | Q36931690 |
| | Integrating costimulatory agonists to optimize immune-based cancer therapies | Q37352989 |
| | Immune-checkpoint blockade and active immunotherapy for glioma | Q37420586 |
| | Late effects of therapy for pediatric brain tumor survivors | Q37617858 |
| | Interferon-gamma in brain tumor immunotherapy. | Q37640598 |
| | Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas | Q37658308 |
| | Cytolytic CD4+T cells in viral immunity | Q37812127 |
| | Tumor-associated neutrophils: new targets for cancer therapy | Q37856086 |
| | Ipilimumab (Yervoy) and the TGN1412 catastrophe | Q37912761 |
| | Tumor-associated neutrophils: friend or foe? | Q37994480 |
| | Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. | Q38110540 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 71 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas | |
| P478 | volume | 8 | |